Researchers at University of Sunderland Have Reported New Data on Anticancer Agents (A Glance Into Factors Affecting the Possible Combined Entrapment of Curcumin and Methylene Blue Into Niosomal Formulations As a Potential Anticancer Therapy).

Researchers at the University of Sunderland in the United Kingdom have conducted a study on the entrapment of two compounds, Methylene blue (MB) and curcumin (CUR), into niosomal formulations for potential anticancer therapy. The study investigated various formulation factors that could affect the entrapment efficiency of the compounds, such as the type of non-ionic surfactants, cholesterol to surfactant ratio, and the concentration of the co-surfactant. The results showed that the optimum composition for encapsulating both compounds was a mol% ratio of 45:45:10 for Span 65, cholesterol, and Cremophor RH40, respectively, with high encapsulation efficiency. The vesicle size of the formulations was found to be suitable for parenteral delivery to target sites. This research has been peer-reviewed and published in the Journal of Drug Delivery Science and Technology. [Extracted from the article]